EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Clemens Kratochwil, Wolfgang P Fendler, Matthias Eiber, Michael S Hofman, Louise Emmett, Jeremie Calais, Joseph R Osborne, Amir Iravani, Phillip Koo, Liza Lindenberg, Richard P Baum, Murat Fani Bozkurt und 18 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2023-07 · 50 (9) · 2830-2845

DOI: 10.1007/s00259-023-06255-8 ↗

Kurz gefasst

Leitlinie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 29.05.2023. Verfasst von Clemens Kratochwil und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany. clemens.kratochwil@med.uni-heidelberg.de. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Nuclear Medicine. Die Arbeit wurde bisher 322-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Universitätsklinikum Heidelberg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified by PSMA PET imaging. Promising results with PSMA-targeted radiopharmaceutical therapy have already been obtained in early-phase studies using various combinations of targeting molecules and radiolabels. Definitive evidence of the safety and efficacy of [ 177 Lu]Lu-PSMA-617 in combination with standard-of-care has been demonstrated in patients with metastatic castration-resistant prostate cancer, whose disease had progressed after or during at least one taxane regimen and at least one novel androgen-axis drug. Preliminary data suggest that 177 Lu-PSMA-radioligand therapy (RLT) also has high potential in additional clinical situations. Hence, the radiopharmaceuticals [ 177 Lu]Lu-PSMA-617 and [ 177 Lu]Lu-PSMA-I&T are currently being evaluated in ongoing phase 3 trials. The purpose of this guideline is to assist nuclear medicine personnel, to select patients with highest potential to benefit from 177 Lu-PSMA-RLT, to perform the procedure in accordance with current best practice, and to prepare for possible side effects and their clinical management. We also provide expert advice, to identify those clinical situations which may justify the off-label use of [ 177 Lu]Lu-PSMA-617 or other emerging ligands on an individual patient basis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantNuclear MedicineMaleHumansProstate-Specific AntigenRadiopharmaceuticalsHeterocyclic Compounds, 1-RingDipeptidesLutetiumTreatment Outcome

Stichwörter der Autor:innen

EANM/SNMMIPSMA[177Lu]Lu-PSMA-617

Substanzen

Prostate-Specific AntigenRadiopharmaceuticalsHeterocyclic Compounds, 1-RingDipeptidesLutetium

Autor:innen und Institutionen

  • Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany. clemens.kratochwil@med.uni-heidelberg.de.
  • Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, 45147, Essen, Germany.
  • Department of Nuclear Medicine, Klinikum Rechts Der Isar, Technical University Munich (TUM), 81675, Munich, Germany.
  • Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Department of Oncology, Sir Peter MacCallum, University of Melbourne, Melbourne, VIC, Australia.
  • Department of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney, Darlinghurst, Australia.

Förderung

  • NCI NIH HHS
  • Universitätsklinikum Heidelberg

Zitieren

APA

Kratochwil, C., Fendler, W. P., Eiber, M., Hofman, M. S., Emmett, L., Calais, J., Osborne, J. R., Iravani, A., Koo, P., Lindenberg, L., Baum, R. P., Bozkurt, M. F., Delgado Bolton, R. C., Ezziddin, S., Forrer, F., Hicks, R. J., Hope, T. A., Kabasakal, L., Konijnenberg, M., …, & Hermann, K. (2023). Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). European Journal of Nuclear Medicine and Molecular Imaging, 50(9), 2830-2845. https://doi.org/10.1007/s00259-023-06255-8

Vancouver

Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, et al. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). European Journal of Nuclear Medicine and Molecular Imaging. 2023;50(9):2830-2845. doi:10.1007/s00259-023-06255-8

BibTeX
@article{Kratochwil2023,
  author = {Kratochwil, Clemens and Fendler, Wolfgang P and Eiber, Matthias and Hofman, Michael S and Emmett, Louise and Calais, Jeremie and Osborne, Joseph R and Iravani, Amir and Koo, Phillip and Lindenberg, Liza and Baum, Richard P and Bozkurt, Murat Fani and Delgado Bolton, Roberto C and Ezziddin, Samer and Forrer, Flavio and Hicks, Rodney J and Hope, Thomas A and Kabasakal, Levent and Konijnenberg, Mark and Kopka, Klaus and Lassmann, Michael and Mottaghy, Felix M and Oyen, Wim J G and Rahbar, Kambiz and Schoder, Heiko and Virgolini, Irene and Bodei, Lisa and Fanti, Stefano and Haberkorn, Uwe and Hermann, Ken},
  title = {Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2023},
  volume = {50},
  number = {9},
  pages = {2830--2845},
  doi = {10.1007/s00259-023-06255-8}
}
Kostenlos starten →